High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-02-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2008-04-152157PMID 19075190PMCID PMC2647674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitors of chronically active ras: potential for treatment of human malignancies.

  2008cited by this paper
• Biochemical and Functional Characterization of Germ Line KRAS Mutations

  2007cited by this paper
• High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

  2007cited by this paper
• Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

  2006cited by this paper
• Recent advances in the research and development of RAF kinase inhibitors.

  2006cited by this paper
• Inherited predispositions and hyperactive Ras in myeloid leukemogenesis

  2006cited by this paper
• Germline KRAS mutations cause Noonan syndrome

  2006cited by this paper
• The Consensus Coding Sequences of Human Breast and Colorectal Cancers

  2006cited by this paper
• Recurrent KRAS codon 146 mutations in human colorectal cancer

  2006cited by this paper
• RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

  2005cited by this paper
• Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

  2005cited by this paper
• Cancer targets in the Ras pathway.

  2005cited by this paper
• Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

  2004cited by this paper
• A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction

  2004cited by this paper
• Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

  2004cited by this paper
• Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

  2004cited by this paper
• Nf1 and Gmcsf interact in myeloid leukemogenesis.

  2000cited by this paper
• Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

  1998cited by this paper
• Mutations of the NF 1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis , Type 1

  1998cited by this paper
• Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.

  1996cited by this paper
• Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia

  1994influential reference
• Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.

  1994cited by this paper
• Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins.

  1993cited by this paper
• How does the switch II region of G‐domains work?

  1993cited by this paper
• Reconstitution of the Raf-1—MEK—ERK Signal Transduction Pathway In Vitro

  1993cited by this paper
• ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK.

  1992cited by this paper
• Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases.

  1992cited by this paper
• Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

  1991cited by this paper
• Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes.

  1988cited by this paper
• Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes.

  1988cited by this paper
• Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins

  1988cited by this paper
• Expression of normal and mutant ras proteins in human acute leukemia.

  1987cited by this paper
• Concurrent mutations in two different ras genes in acute myelocytic leukemias.

  1987cited by this paper
• RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

  1987cited by this paper

• Clonal dynamics of chronic myelomonocytic leukemia progression: paired‐sample comparison

  2025cites this paper
• A Novel Prognostic Risk‐Scoring Model Based on RAS Gene‐Associated Cluster in Pediatric Acute Myeloid Leukemia

  2025cites this paper
• A Step-wise, Deterministic and Fatal Mouse Model of Myeloid Neoplasm with Spontaneous Acquisition of Patient-relevant RTK–RAS Mutations

  2025influential citation
• Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives

  2025cites this paper
• Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity

  2024cites this paper
• Rigorous software pipeline for clinical somatic mutation analyses of solid tumors

  2023cites this paper
• Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

  2023cites this paper
• Random walk with restart on multilayer networks: from node prioritisation to supervised link prediction and beyond

  2023cites this paper
• Screening for ELANE, HAX1 and GFI1 gene mutations in children with neutropenia and clinical characterization of two novel mutations in ELANE gene

  2023cites this paper
• Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

  2022cites this paper
• Rare Presentation of FLT3-ITD-Positive Acute Myeloid Leukemia With Monocytic Differentiation: A Case Report

  2022cites this paper
• Computational Analysis of Deleterious SNPs in NRAS to Assess Their Potential Correlation With Carcinogenesis

  2022cites this paper
• Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects

  2022cites this paper
• Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia

  2021cites this paper
• Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects.

  2021cites this paper
• Universal multilayer network exploration by random walk with restart

  2021cites this paper
• A concise review on the molecular genetics of acute myeloid leukemia.

  2021cites this paper
• Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics

  2021influential citation
• Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age-specific mouse model.

  2020cites this paper
• A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks

  2020cites this paper
• The effects of mutant Ras proteins on the cell signalome

  2020cites this paper
• Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients

  2020cites this paper
• The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer

  2020cites this paper
• Targeting the untargetable KRAS in cancer therapy

  2019cites this paper
• Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells

  2019cites this paper
• A Comparative Analysis of Individual RAS Mutations in Cancer Biology

  2019influential citation
• Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

  2019cites this paper
• Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases

  2019cites this paper
• Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN)

  2018cites this paper
• The Cooperative Relationship between STAT5 and Reactive Oxygen Species in Leukemia: Mechanism and Therapeutic Potential

  2018cites this paper
• The Function of Rab35 in Development and Disease

  2018cites this paper
• TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells

  2018cites this paper
• The Function of Rab 35 in evelop ent and isease

  2018cites this paper
• Emerging molecular predictive and prognostic factors in acute myeloid leukemia

  2018cites this paper
• Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm.

  2018cites this paper
• Novel pathogenic variant in the HRAS gene with lethal outcome and a broad phenotypic spectrum among Polish patients with Costello syndrome

  2017cites this paper
• Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR

  2017cites this paper
• A High-Resolution Genome-Wide CRISPR/Cas9 Viability Screen Reveals Structural Features and Contextual Diversity of the Human Cell-Essential Proteome

  2017cites this paper
• ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm

  2017cites this paper
• MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.

  2017cites this paper
• Genomic determinants of chronic myelomonocytic leukemia

  2017cites this paper
• The Role of the RAS Signaling Pathway in the Pathophysiology of Chronic Myelomonocytic Leukemia – New Insights from Molecular and Biologic Characterization

  2017cites this paper
• Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C2 and C6 positions.

  2017cites this paper
• Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

  2017cites this paper
• Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations.

  2017cites this paper
• A review of methods for nematode identification.

  2017cites this paper
• Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

  2016cites this paper
• Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia

  2016cites this paper
• n-ras and k-ras Mutations Among Some Iraqi Patients with Acute Lymphoblastic Leukemia

  2016cites this paper
• Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

  2016cites this paper
• Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing

  2015cites this paper
• EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells

  2015cites this paper
• The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia

  2015cites this paper
• Cooperation between Noncanonical Ras Network Mutations.

  2015cites this paper
• Mutant HRAS as novel target for MEK and mTOR inhibitors

  2015cites this paper
• RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data

  2015cites this paper
• Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization.

  2015cites this paper
• Identification of an oncogenic RAB protein

  2015cites this paper
• An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences

  2015influential citation
• The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway

  2015cites this paper
• The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias

  2015cites this paper
• Individualized chemical systems medicine of acute and chronic myeloid leukemia

  2015cites this paper
• Cooperation between Noncanonical Ras Network Mutations in Cancer

  2014cites this paper
• Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

  2014cites this paper
• BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS

  2014cites this paper
• Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

  2014cites this paper
• Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

  2014cites this paper
• Genomic tools in acute myeloid leukemia: From the bench to the bedside

  2014cites this paper
• Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia

  2014influential citation
• Prognostic score including gene mutations in chronic myelomonocytic leukemia.

  2013cites this paper
• Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

  2013cites this paper
• A molecular case report

  2013cites this paper
• Lack of KRAS gene mutations in chronic myeloid leukemia in Iran.

  2013cites this paper
• N-ras Mutation Detection by Pyrosequencing in Adult Patients with Acute Myeloid Leukemia at a Single Institution

  2013cites this paper
• Clonal architecture of chronic myelomonocytic leukemias.

  2013cites this paper
• Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

  2013cites this paper
• Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells

  2013cites this paper
• Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia

  2013cites this paper
• Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

  2013cites this paper
• Utility of Multiplex Mutation Analysis in the Diagnosis of Chronic Myelomonocytic Leukemia

  2013cites this paper
• Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

  2013cites this paper
• DNA Extraction and Purification

  2013cites this paper
• Extraction et purification de l’ADN

  2013cites this paper
• Induction of Histiocytic Sarcoma in Mouse Skeletal Muscle

  2012cites this paper
• Targeting oncogenic Ras signaling in hematologic malignancies.

  2012cites this paper
• Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

  2012cites this paper
• Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia

  2012cites this paper
• Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine

  2012cites this paper
• Sérum fœtal bovin

  2012cites this paper
• Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?

  2012cites this paper
• Current status of allogeneic HST for chronic myelomonocytic leukemia

  2012cites this paper
• The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

  2012cites this paper
• High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.

  2012influential citation
• Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations

  2012cites this paper
• Fetal Bovine Serum

  2012cites this paper
• Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

  2012cites this paper
• BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

  2012cites this paper
• Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia

  2012cites this paper
• Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia

  2012cites this paper
• Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

  2011cites this paper